OraSure Technologies (NASDAQ:OSUR) Raised to Hold at Wall Street Zen

OraSure Technologies (NASDAQ:OSUR) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued to clients and investors on Saturday.

Separately, Weiss Ratings upgraded OraSure Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Thursday, June 4th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Reduce” and an average price target of $3.00.

OraSure Technologies Price Performance

Shares of OraSure Technologies stock opened at $3.97 on Friday. The company’s fifty day simple moving average is $4.08 and its 200-day simple moving average is $3.33. The stock has a market capitalization of $273.33 million, a PE ratio of -3.82 and a beta of 1.01. OraSure Technologies has a 1-year low of $2.08 and a 1-year high of $4.58.

Insider Transactions at OraSure Technologies

In other news, Director Steven Kyle Boyd bought 25,000 shares of the firm’s stock in a transaction on Thursday, May 14th. The shares were bought at an average price of $2.99 per share, for a total transaction of $74,750.00. Following the purchase, the director owned 113,462 shares in the company, valued at approximately $339,251.38. The trade was a 28.26% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 4.70% of the company’s stock.

Hedge Funds Weigh In On OraSure Technologies

A number of hedge funds have recently modified their holdings of OSUR. Sei Investments Co. raised its position in shares of OraSure Technologies by 16.4% during the 3rd quarter. Sei Investments Co. now owns 32,244 shares of the medical instruments supplier’s stock valued at $103,000 after purchasing an additional 4,536 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of OraSure Technologies by 13.3% during the 4th quarter. Russell Investments Group Ltd. now owns 43,636 shares of the medical instruments supplier’s stock valued at $106,000 after buying an additional 5,138 shares in the last quarter. Hsbc Holdings PLC boosted its holdings in OraSure Technologies by 4.6% in the 1st quarter. Hsbc Holdings PLC now owns 141,309 shares of the medical instruments supplier’s stock worth $421,000 after buying an additional 6,218 shares during the period. BNP Paribas Financial Markets boosted its holdings in OraSure Technologies by 102.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 15,275 shares of the medical instruments supplier’s stock worth $49,000 after buying an additional 7,720 shares during the period. Finally, Envestnet Asset Management Inc. boosted its holdings in OraSure Technologies by 32.7% in the 2nd quarter. Envestnet Asset Management Inc. now owns 33,018 shares of the medical instruments supplier’s stock worth $99,000 after buying an additional 8,133 shares during the period. 93.50% of the stock is currently owned by institutional investors.

About OraSure Technologies

OraSure Technologies, Inc is a Bethlehem, Pennsylvania–based diagnostic and medical device company specializing in the development, manufacture and commercialization of point-of-care and self-testing products. Founded in 1988, OraSure has built a portfolio of oral fluid and other non-invasive specimen collection technologies that support the detection of infectious diseases, drugs of abuse, and health and wellness biomarkers.

The company’s flagship product, the OraQuick® rapid HIV test, was the first Food and Drug Administration–approved over-the-counter oral fluid test for the detection of HIV-1/2 antibodies.